CA2343376A1 - Sustained release ranolazine formulations - Google Patents
Sustained release ranolazine formulations Download PDFInfo
- Publication number
- CA2343376A1 CA2343376A1 CA002343376A CA2343376A CA2343376A1 CA 2343376 A1 CA2343376 A1 CA 2343376A1 CA 002343376 A CA002343376 A CA 002343376A CA 2343376 A CA2343376 A CA 2343376A CA 2343376 A1 CA2343376 A1 CA 2343376A1
- Authority
- CA
- Canada
- Prior art keywords
- ranolazine
- sustained release
- release ranolazine
- aqueous media
- ranolazine formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng basNmL.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9980498P | 1998-09-10 | 1998-09-10 | |
US60/099,804 | 1998-09-10 | ||
US09/321,522 US6303607B1 (en) | 1998-09-10 | 1999-05-27 | Method for administering a sustained release ranolanolazine formulation |
US09/321,522 | 1999-05-27 | ||
PCT/US1999/020968 WO2000013687A2 (en) | 1998-09-10 | 1999-09-09 | Sustained release ranolazine formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2343376A1 true CA2343376A1 (en) | 2000-03-16 |
CA2343376C CA2343376C (en) | 2007-01-09 |
Family
ID=26796494
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002342390A Expired - Lifetime CA2342390C (en) | 1998-09-10 | 1999-09-09 | Sustained release ranolazine formulations |
CA002343376A Expired - Lifetime CA2343376C (en) | 1998-09-10 | 1999-09-09 | Sustained release ranolazine formulations |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002342390A Expired - Lifetime CA2342390C (en) | 1998-09-10 | 1999-09-09 | Sustained release ranolazine formulations |
Country Status (33)
Country | Link |
---|---|
US (14) | US6303607B1 (en) |
EP (3) | EP1527779A1 (en) |
JP (2) | JP3745621B2 (en) |
KR (1) | KR100475759B1 (en) |
CN (2) | CN1193757C (en) |
AR (3) | AR022085A1 (en) |
AT (2) | ATE285774T1 (en) |
AU (4) | AU760435B2 (en) |
BR (2) | BR9913553A (en) |
CA (2) | CA2342390C (en) |
CY (1) | CY2008020I1 (en) |
CZ (2) | CZ301341B6 (en) |
DE (3) | DE69922964T2 (en) |
DK (2) | DK1096937T3 (en) |
ES (2) | ES2177346T3 (en) |
FR (1) | FR09C0001I2 (en) |
GE (1) | GEP20053420B (en) |
HK (2) | HK1040060A1 (en) |
HU (2) | HUP0104088A3 (en) |
IL (6) | IL141893A0 (en) |
LU (1) | LU91504I2 (en) |
MX (2) | MXPA01002599A (en) |
NL (1) | NL300371I2 (en) |
NO (4) | NO319434B1 (en) |
NZ (2) | NZ510386A (en) |
PL (3) | PL202207B1 (en) |
PT (2) | PT1096937E (en) |
RU (2) | RU2207856C2 (en) |
SI (2) | SI1109558T1 (en) |
TR (2) | TR200101262T2 (en) |
TW (1) | TWI241911B (en) |
UA (2) | UA75027C2 (en) |
WO (2) | WO2000013687A2 (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
IL151014A0 (en) * | 2000-02-18 | 2003-02-12 | Cv Therapeutics Inc | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
AU2001277938A1 (en) * | 2000-07-21 | 2002-02-05 | Cv Therapeutics, Inc. | Method for treating angina |
AU2001211213A1 (en) * | 2000-10-20 | 2002-04-29 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
US8101209B2 (en) * | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
FR2830447B1 (en) * | 2001-10-09 | 2004-04-16 | Flamel Tech Sa | MICROPARTICULAR ORAL GALENIC FORM FOR DELAYED AND CONTROLLED RELEASE OF PHARMACEUTICAL ACTIVE INGREDIENTS |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
PT1492511E (en) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
WO2003084517A2 (en) * | 2002-04-09 | 2003-10-16 | Flamel Technologies | Oral suspension of amoxicillin capsules |
CN100551370C (en) | 2002-05-21 | 2009-10-21 | Cv医药有限公司 | The application of ranolazine in the pharmaceutical composition of preparation treatment diabetes |
US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
GB0403098D0 (en) | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
CN101098682A (en) * | 2005-01-06 | 2008-01-02 | Cv医药有限公司 | Sustained release pharmaceutical formulations comprising ranolazine |
FR2886150B1 (en) * | 2005-05-24 | 2007-08-24 | Flamel Technologies Sa | ORAL PHARMACEUTICAL FORM BASED ON AT LEAST ONE ACTIVE INGREDIENT WHOSE SOLUBILITY VARIES IN ACCORDANCE WITH THE CONDITIONS OF GASTRIC PH |
JP2009502957A (en) * | 2005-07-28 | 2009-01-29 | スパーナス ファーマシューティカルズ インコーポレイテッド | Sustained release tablet formulation with improved mechanical properties |
US20090091253A1 (en) * | 2006-03-17 | 2009-04-09 | Konica Minolta Holdings, Inc. | Organic electroluminescent element, display device and lighting device |
FI20060501L (en) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Composition and method for binding acetaldehyde in the stomach |
CA2677931A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
CA2678325A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20090312340A1 (en) * | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
CA2678319A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
ES2395241T3 (en) * | 2007-03-07 | 2013-02-11 | Concert Pharmaceuticals Inc. | Deuterated piperazine derivatives as antianginal compounds |
WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
CN101066253B (en) * | 2007-06-07 | 2011-01-05 | 北京本草天源药物研究院 | Slow releasing ranolazine tablet |
JP2010529994A (en) * | 2007-06-13 | 2010-09-02 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | Substituted piperazine |
US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20090076018A1 (en) * | 2007-09-15 | 2009-03-19 | Protia, Llc | Deuterium-enriched ranolazine |
BRPI0908428A2 (en) * | 2008-02-06 | 2015-12-08 | Gilead Sciences Inc | use of ranozaline to treat pain. |
AU2010248948A1 (en) * | 2009-05-14 | 2011-12-01 | Gilead Sciences, Inc. | Ranolazine for the treatment of CNS disorders |
EP2515880B1 (en) | 2009-05-28 | 2019-11-27 | Lupin Limited | Novel pharmaceutical compositions of ranolazine |
MX2012003362A (en) * | 2009-09-25 | 2012-06-27 | Lupin Ltd | Sustained release composition of ranolazine. |
TWI508726B (en) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | Method of treating atrial fibrillation |
TW201215392A (en) | 2010-06-16 | 2012-04-16 | Gilead Sciences Inc | Use of ranolazine for treating pulmonary hypertension |
EP2524688B1 (en) | 2011-05-11 | 2013-05-01 | ratiopharm GmbH | Composition for modified release comprising ranolazine |
NO3175985T3 (en) | 2011-07-01 | 2018-04-28 | ||
EP2758053A1 (en) | 2011-09-21 | 2014-07-30 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
WO2014176557A2 (en) * | 2013-04-26 | 2014-10-30 | Chanrx Corporation | Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals |
CN104758265B (en) * | 2014-01-07 | 2019-05-17 | 四川海思科制药有限公司 | A kind of ranolazine sustained release tablet medicament composition and preparation method thereof |
TW201618783A (en) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on BTK occupancy and BTK resynthesis rate |
TW201717919A (en) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | Ranolazine multiple compressed tablets |
WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
AR110252A1 (en) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | FUSIONED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE QUINASA CAM |
US10898444B2 (en) | 2017-06-01 | 2021-01-26 | Sun Pharmaceutical Industries Limited | Extended release multiparticulates of ranolazine |
CN112438955A (en) * | 2019-08-30 | 2021-03-05 | 深圳翰宇药业股份有限公司 | Ranolazine sustained-release composition and preparation method thereof |
JP2023507626A (en) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス,インコーポレイテッド | Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF) |
CN110898024A (en) * | 2019-12-17 | 2020-03-24 | 卓和药业集团有限公司 | Pharmaceutical composition for treating angina pectoris and preparation method thereof |
GR1010345B (en) * | 2021-12-16 | 2022-11-28 | Φαρματεν Α.Β.Ε.Ε., | Prolonged release tablets comprising ranolazine and method of preparation therof |
GR1010510B (en) * | 2022-06-07 | 2023-07-20 | Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, | Solid sustained- release pharmaceutical forms of ranolazine |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4567264A (en) | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
AU633589B2 (en) * | 1989-06-23 | 1993-02-04 | Syntex (U.S.A.) Inc. | Novel methods of treatment using ranolazine and related piperazine derivatives |
US5527545A (en) | 1989-09-18 | 1996-06-18 | Recordati S.A. Chemical And Pharmaceutical Company | Liquid-suspension controlled-release pharmaceutical composition |
US5209933A (en) * | 1990-01-10 | 1993-05-11 | Syntex (U.S.A.) Inc. | Long acting calcium channel blocker composition |
JP2516524B2 (en) * | 1992-04-27 | 1996-07-24 | 大洋薬品工業株式会社 | Persistent formulation |
JPH06199657A (en) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | Sustained release pharmaceutical preparation |
US5455045A (en) | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
JPH07112932A (en) * | 1993-08-27 | 1995-05-02 | Mitsui Toatsu Chem Inc | Sustained release medicine preparation |
US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
JPH08259446A (en) * | 1995-01-24 | 1996-10-08 | Mitsui Toatsu Chem Inc | Sustained action pharmaceutical preparation |
JPH08310946A (en) * | 1995-05-19 | 1996-11-26 | Yuutoku Yakuhin Kogyo Kk | Percutaneous absorbable pharmaceutical preparation |
JPH09188617A (en) * | 1996-01-08 | 1997-07-22 | Pola Chem Ind Inc | Medicinal composition of sustained release |
US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
-
1999
- 1999-05-27 US US09/321,522 patent/US6303607B1/en not_active Expired - Lifetime
- 1999-09-09 RU RU2001109432/14A patent/RU2207856C2/en active
- 1999-09-09 JP JP2000568494A patent/JP3745621B2/en not_active Expired - Lifetime
- 1999-09-09 UA UA2001031622A patent/UA75027C2/en unknown
- 1999-09-09 AT AT99948196T patent/ATE285774T1/en active
- 1999-09-09 EP EP04030151A patent/EP1527779A1/en not_active Withdrawn
- 1999-09-09 KR KR10-2001-7003126A patent/KR100475759B1/en not_active IP Right Cessation
- 1999-09-09 CA CA002342390A patent/CA2342390C/en not_active Expired - Lifetime
- 1999-09-09 DK DK99948196T patent/DK1096937T3/en active
- 1999-09-09 MX MXPA01002599A patent/MXPA01002599A/en active IP Right Grant
- 1999-09-09 CN CNB998108367A patent/CN1193757C/en not_active Expired - Lifetime
- 1999-09-09 CA CA002343376A patent/CA2343376C/en not_active Expired - Lifetime
- 1999-09-09 IL IL14189399A patent/IL141893A0/en active IP Right Grant
- 1999-09-09 GE GE4322A patent/GEP20053420B/en unknown
- 1999-09-09 AU AU61425/99A patent/AU760435B2/en not_active Revoked
- 1999-09-09 ES ES99968627T patent/ES2177346T3/en not_active Expired - Lifetime
- 1999-09-09 IL IL14189299A patent/IL141892A0/en active IP Right Grant
- 1999-09-09 PL PL381164A patent/PL202207B1/en unknown
- 1999-09-09 DE DE69922964T patent/DE69922964T2/en not_active Expired - Lifetime
- 1999-09-09 HU HU0104088A patent/HUP0104088A3/en unknown
- 1999-09-09 RU RU2001109431/14A patent/RU2214233C2/en active Protection Beyond IP Right Term
- 1999-09-09 EP EP99948196A patent/EP1096937B9/en not_active Expired - Lifetime
- 1999-09-09 TR TR2001/01262T patent/TR200101262T2/en unknown
- 1999-09-09 EP EP99968627A patent/EP1109558B1/en not_active Expired - Lifetime
- 1999-09-09 PT PT99948196T patent/PT1096937E/en unknown
- 1999-09-09 DE DE69901570T patent/DE69901570T2/en not_active Expired - Lifetime
- 1999-09-09 PL PL348249A patent/PL196263B1/en unknown
- 1999-09-09 CZ CZ20010880A patent/CZ301341B6/en not_active IP Right Cessation
- 1999-09-09 AU AU60364/99A patent/AU744071B2/en not_active Revoked
- 1999-09-09 HU HU0103844A patent/HU224215B1/en active Protection Beyond IP Right Term
- 1999-09-09 DE DE122008000065C patent/DE122008000065I1/en active Pending
- 1999-09-09 CN CNB998108359A patent/CN1211086C/en not_active Expired - Lifetime
- 1999-09-09 BR BR9913553-1A patent/BR9913553A/en not_active Application Discontinuation
- 1999-09-09 AT AT99968627T patent/ATE217794T1/en active
- 1999-09-09 SI SI9930078T patent/SI1109558T1/en unknown
- 1999-09-09 SI SI9930749T patent/SI1096937T1/en unknown
- 1999-09-09 WO PCT/US1999/020968 patent/WO2000013687A2/en active Application Filing
- 1999-09-09 DK DK99968627T patent/DK1109558T3/en active
- 1999-09-09 CZ CZ20010879A patent/CZ301375B6/en not_active IP Right Cessation
- 1999-09-09 ES ES99948196T patent/ES2234302T3/en not_active Expired - Lifetime
- 1999-09-09 BR BR9913626-0A patent/BR9913626A/en not_active Application Discontinuation
- 1999-09-09 PT PT99968627T patent/PT1109558E/en unknown
- 1999-09-09 AR ARP990104545A patent/AR022085A1/en active IP Right Grant
- 1999-09-09 TR TR2001/01261T patent/TR200101261T2/en unknown
- 1999-09-09 NZ NZ510386A patent/NZ510386A/en not_active IP Right Cessation
- 1999-09-09 PL PL347073A patent/PL196668B1/en unknown
- 1999-09-09 NZ NZ510384A patent/NZ510384A/en not_active IP Right Cessation
- 1999-09-09 UA UA2001031623A patent/UA67793C2/en unknown
- 1999-09-09 WO PCT/US1999/020967 patent/WO2000013686A2/en active IP Right Grant
- 1999-09-09 MX MXPA01002598A patent/MXPA01002598A/en active IP Right Grant
-
2000
- 2000-03-29 US US09/538,337 patent/US6369062B1/en not_active Expired - Lifetime
- 2000-05-30 TW TW088115657A patent/TWI241911B/en not_active IP Right Cessation
-
2001
- 2001-03-07 IL IL141893A patent/IL141893A/en not_active IP Right Cessation
- 2001-03-07 IL IL141892A patent/IL141892A/en not_active IP Right Cessation
- 2001-03-08 NO NO20011191A patent/NO319434B1/en not_active IP Right Cessation
- 2001-03-08 NO NO20011192A patent/NO320986B1/en not_active IP Right Cessation
- 2001-08-09 US US09/925,871 patent/US6525057B2/en not_active Expired - Lifetime
- 2001-10-19 US US10/041,521 patent/US6503911B2/en not_active Expired - Lifetime
-
2002
- 2002-03-08 HK HK02101777A patent/HK1040060A1/en not_active IP Right Cessation
- 2002-08-10 HK HK02105856.0A patent/HK1044284B/en not_active IP Right Cessation
- 2002-09-25 US US10/254,707 patent/US6562826B1/en not_active Expired - Lifetime
- 2002-09-27 US US10/256,993 patent/US6620814B2/en not_active Expired - Lifetime
- 2002-09-27 US US10/259,143 patent/US6617328B2/en not_active Expired - Lifetime
-
2003
- 2003-03-05 US US10/382,266 patent/US6852724B2/en not_active Expired - Lifetime
- 2003-07-07 US US10/614,420 patent/US20040097514A1/en not_active Abandoned
- 2003-07-07 US US10/614,460 patent/US6864258B2/en not_active Expired - Lifetime
-
2004
- 2004-10-21 US US10/969,891 patent/US20050059667A1/en not_active Abandoned
-
2005
- 2005-01-06 US US11/031,220 patent/US20050153982A1/en not_active Abandoned
- 2005-09-07 US US11/221,450 patent/US20060147521A1/en not_active Abandoned
- 2005-09-20 NO NO20054324A patent/NO20054324L/en unknown
- 2005-10-11 JP JP2005296674A patent/JP2006096757A/en active Pending
- 2005-11-02 US US11/265,536 patent/US20060217397A1/en not_active Abandoned
-
2006
- 2006-02-24 AR ARP060100699A patent/AR053440A2/en not_active Application Discontinuation
- 2006-02-24 AR ARP060100700A patent/AR052921A1/en not_active Application Discontinuation
- 2006-05-01 IL IL175371A patent/IL175371A0/en unknown
-
2007
- 2007-01-22 IL IL180864A patent/IL180864A0/en unknown
-
2008
- 2008-09-03 AU AU2008207703A patent/AU2008207703A1/en active Pending
- 2008-09-03 AU AU2008207707A patent/AU2008207707A1/en active Pending
- 2008-11-27 NL NL300371C patent/NL300371I2/en unknown
- 2008-12-03 LU LU91504C patent/LU91504I2/en unknown
- 2008-12-30 CY CY2008020C patent/CY2008020I1/en unknown
-
2009
- 2009-01-05 FR FR09C0001C patent/FR09C0001I2/fr active Active
- 2009-03-05 NO NO2009005C patent/NO2009005I1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2343376A1 (en) | Sustained release ranolazine formulations | |
CA2402222A1 (en) | Sustained release ranolazine formulations | |
WO1997045091A3 (en) | Sustained release oxycodone formulations with no fed/fast effect | |
WO2002045684A3 (en) | Rapidly dispersing pharmaceutical composition comprising effervescent agents | |
AU2002229573A1 (en) | Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives | |
CA2112014A1 (en) | Antiallergic composition for ophthalmic or nasal use | |
IL123638A0 (en) | Microemulsions for use as vehicles for administration of active compounds | |
CA2258841A1 (en) | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug | |
HK12495A (en) | Pharmaceutical formulations | |
CA2164776A1 (en) | Pharmaceutical, orally applicable composition | |
AU679200B2 (en) | Effervescent pharmaceutical composition containing ibuprofenand method for preparing same | |
HUP0002902A3 (en) | 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions | |
AU7588696A (en) | Pyrido{2, 3-D} pyrimidine derivatives and pharmaceutical compositions thereof | |
CA2341297A1 (en) | Dosage form comprising liquid formulation | |
CA2338794A1 (en) | New oral formulation for 5-ht4 agonists or antagonists | |
GR1002907B (en) | Coated trimeboutine maleate tablet | |
CA2176223A1 (en) | Fenbendazole formulations | |
AU3669700A (en) | 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient | |
CA2285985A1 (en) | A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water | |
HK1045937A1 (en) | Pharmaceutical compositions for oral administration of phloroglucinol and preparation thereof | |
IE893578L (en) | Phenyloxypropanolamine derivatives, their preparation and¹their application in therapeutics | |
AU5415699A (en) | Water-soluble pharmaceutical formulation for administering sildenafil | |
AU4874301A (en) | Medicinal compositions containing camptothecin derivative and ph regulating agent | |
AU7191891A (en) | Water soluble salts of purpuromycin and pharmaceutical formulations thereof | |
CA2223014A1 (en) | Controlled release formulation having a preformed passageway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20190909 |